Alnylam, Bayer, Boehringer Ingelheim, and Novo Nordisk will collaborate with PRECISE to analyze whole-genome and other data on 100,000 Singaporeans.

The study will test the combination, which aims to boost CD19 expression to make CAR T-cell therapy more effective, in patients with solid tumors.

The partners will also leverage AI tools and proprietary evaluation models to home in on targetable shared cancer antigens and develop vaccines against them.

Tessera will receive $150 million in upfront cash and equity investment from Regeneron and be eligible for up to $125 million in milestone payments.